Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient
care. It is applicable to specialists, primary care, and providers at all levels. is Guideline
should not be considered exclusive of other methods of care reasonably directed at obtaining the
same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated
with the distributor of this clinical reference tool.
Abbreviations
AFB, acid-fast bacilli; CCR5, C chemokine receptor type 5; CYP, cytochrome
P450; DOT, directly observed therapy; EMB, ethambutol; FDA, US Food and Drug
Administration; HIV, human immunodeficiency virus; IGRA, interferon-γ release
assay; IM, intramuscular; INH, isoniazid; INSTI, integrase strand transfer inhibitor;
IV, intravenous; Mtb, Mycobacterium tuberculosis; NNRTI, nonnucleoside reverse
transcriptase inhibitor; PZA, pyrazinamide; RFB, rifabutin; RIF, rifampin; RPT,
rifapentine; SAT, self-administered therapy; TDF, tenofovir disoproxil fumarate; TDM,
therapeutic drug monitoring ; TNF, tumor necrosis factor; TSH, thyroid-stimulating
hormone; TST, tuberculin skin test
e guidelines provide evidence-based recommendations that have been developed
using GR ADE (Grading of Recommendations Assessment, Development, and
Evaluation) methodolog y. GR ADE involves structured literature review, systematic
reviews and meta-analyses of combined data, and expert discussion to assess the
certainty in the evidence and determine the strength of each recommendation.
Source
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, Chaisson LH,
Chaisson RE, Daley CL, Grzemska M, Higashi JM, Ho CS, Hopewell PC, Keshavjee SA,
Lienhardt C, Menzies R, Merrifield C, Narita M, O'Brien R, Peloquin CA, Raery A,
Saukkonen J, Schaaf HS, Sotgiu G, Starke JR, Migliori GB, Vernon A. Official American
oracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society
of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis.
Clin Infect Dis. 2016;63(7):e147-195. doi: 10.1093/cid/ciw376. Epub 2016 Aug 10.
PMID: 27516382
e guidelines were a cooperative effort among the American oracic Society, Centers for
Disease Control and Prevention, and Infectious Diseases Society of America
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
For additional copies, order at GuidelineCentral.com
Copyright © 2016 All rights reserved
IDSATUB16113
